ClinicalTrials.gg
CompletedNCT07479641Updated Sep 21, 2026

A Bioequivalence Study of Two Formulations of HRS-1893 Tablets in Healthy Participants

A Phase 1 interventional study of Test formulation of HRS-1893 tablet and Reference formulation of HRS-1893 tablet in Cardiomyopathy, sponsored by Shandong Suncadia Medicine Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-21.

Sponsored by Shandong Suncadia Medicine Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
58
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 25 studies in Cardiomyopathies with a site in China — 12 open to participants now, 12 under way, 1 of them phase 3. Cardiomyopathies · China.

Enrollment
9th of 13
58 · median 96
Started
2026
with 2 others
Phase 1
4 of 25
1 open now
Registered
22nd of 25
by date
Lead sponsor
3 of 25
Shandong Suncadia Medicine Co., Ltd.

Among the 25 studies in Cardiomyopathies with a site in China, this one is the 9th largest by enrollment of the 13 interventional ones that give a count, is one of 3 that started in 2026, is one of 4 in phase 1, and was the 22nd registered.

Cardiomyopathies

553 studies on the registry are indexed under Cardiomyopathies; 151 are open to participants now.

Browse Cardiomyopathies studies →

Open to participants now

12 of the 25 studies in Cardiomyopathies with a site in China are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 115 Cardiomyopathies studies recruiting now, 70 (61%) set no upper age limit and 17 (15%) stop at 75 or younger; 35 take children under 18; 22 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies in Cardiomyopathies with a site in China, or all of them as a file.
02

Study summary

This study will investigate the bioequivalence between two formulations of HRS-1893 tablets. Safety and tolerability will also be assessed.

03

Conditions studied

  • Cardiomyopathy

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects aged 18 to 55 years (inclusive), regardless of gender;
  2. (BMI) between 19 and 28 kg/m² (inclusive), with body weight ≥ 50.0 kg and \< 90.0 kg for men, and ≥ 45.0 kg and \< 90.0 kg for women;
  3. No abnormalities of clinical significance are found upon comprehensive physical examination and laboratory tests, or only minor abnormalities that are deemed by the investigator not to affect the subject's eligibility for enrollment;
  4. No abnormalities on the 12-lead ;
  5. The subject must understand the study procedures and methods, voluntarily agree to participate, and provide written .

Exclusion criteria

Exclusion Criteria:

  1. Subjects with suspected to the drug or any ;
  2. The subject has a history of syncope;
  3. Exclusion due to blood pressure: Systolic Blood Pressure (SBP) >140 mmHg or \<90 mmHg; OR Diastolic Blood Pressure (DBP) >90 mmHg or \<60 mmHg, as determined by the investigator to be ;
  4. History of gastric or intestinal surgery that, in the investigator's judgment, may affect drug absorption;
  5. A positive result in any one of the following infectious disease screening tests during the screening period: surface antigen (HBsAg), virus antibody (HCV-Ab), treponema pallidum antibody (syphilis), or antibody/antigen (HIV-Ab/Ag);
  6. Subjects who meet any of the following criteria will be excluded: a. Smoking: Average daily cigarette consumption of more than 5 cigarettes within the 4 weeks prior to screening; b. Alcohol: Average daily alcohol intake exceeding 15 g within one week prior to screening (15 g of alcohol is equivalent to 450 mL of beer, 150 mL of wine, or 50 mL of low-alcohol spirits); c. Non-compliance: Inability or unwillingness to abstain from smoking, alcohol, and caffeine-containing foods or beverages during the screening period and the entire study duration; d. Diet: Have special dietary requirements, cannot comply with the standardized diet provided in the study, or have a history of substance abuse;
  7. History of substance abuse;
  8. Use of any prescription drugs, over-the-counter medications, or Chinese herbal medicines within 1 month prior to dosing, or the use of any drug within 5 half-lives prior to screening (whichever is longer). Additionally, subjects who plan to take any non-study medications during the trial period will be excluded;
  9. Any other circumstances that, in the investigator's judgment, make the subject unsuitable for participation in the trial. This includes physiological or psychological conditions that may increase the trial risk, affect the subject's protocol compliance, or impact the subject's ability to complete the study.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
58 participants (actual)

Study arms

  • Experimental
    HRS-1893 test formulation group

    Drug: Test formulation of HRS-1893 tablet

  • Experimental
    HRS-1893 reference formulation group

    Drug: Reference formulation of HRS-1893 tablet

Interventions

  • DrugTest formulation of HRS-1893 tablet

    Test formulation of HRS-1893 tablet, oral.

  • DrugReference formulation of HRS-1893 tablet

    Reference formulation of HRS-1893 tablet, oral.

06

What researchers measure

Primary outcomes

  1. Peak concentration (Cmax).

    Primary Pharmacokinetic (PK) parameters of different HRS-1893 formulations in healthy subjects.

    Time frame: From Day 1 to Day 17.

  2. Area under the plasma concentration - time curve from Time 0 to the last quantifiable time point (AUC0-t).

    Primary Pharmacokinetic (PK) parameters of different HRS-1893 formulations in healthy subjects.

    Time frame: From Day 1 to Day 17.

  3. Area under the plasma concentration - time curve from Time 0 to infinity (AUC0-∞).

    Primary pharmacokinetic (PK) parameters of different HRS-1893 formulations in healthy subjects.

    Time frame: From Day 1 to Day 17.

Secondary outcomes

  1. Time to peak concentration (Tmax).

    Other primary pharmacokinetic (PK) parameters of different HRS-1893 formulations in healthy subjects.

    Time frame: From Day 1 to Day 17.

  2. Elimination half-life (t1/2).

    Other primary pharmacokinetic (PK) parameters of different HRS-1893 formulations in healthy subjects.

    Time frame: From Day 1 to Day 17.

  3. Apparent clearance (CL/F).

    Other primary pharmacokinetic (PK) parameters of different HRS-1893 formulations in healthy subjects.

    Time frame: From Day 1 to Day 17.

  4. Apparent volume of distribution (Vz/F).

    Other primary pharmacokinetic (PK) parameters of different HRS-1893 formulations in healthy subjects.

    Time frame: From Day 1 to Day 17.

  5. Incidence and severity of any adverse events (AEs).

    Safety and tolerability of different HRS-1893 formulations in healthy subjects.

    Time frame: From Day 1 to Day 21 ± 2.

  6. 12-Lead Electrocardiogram (ECG) QT Interval.

    Safety and tolerability of different HRS-1893 formulations in healthy subjects.

    Time frame: From Day 1 to Day 21 ± 2.

  7. Transthoracic echocardiogram (TTE) results.

    Safety and tolerability of different HRS-1893 formulations in healthy subjects.

    Time frame: From Day 1 to Day 21 ± 2.

  8. Vital signs results - blood pressure.

    Safety and tolerability of different HRS-1893 formulations in healthy subjects.

    Time frame: From Day 1 to Day 21 ± 2.

07

Study locations

1 site
  • Beijing Hospital
    Beijing, Beijing Municipality 100730, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2026 to primary completion in Sep 2026, 5 months.

Of 16 phase 1 interventional studies under Cardiomyopathies, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 58. This study's 5 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 11, 2026
First posted
Mar 18, 2026
StartActual
Apr 14, 2026
Primary completionActual
Sep 14, 2026
CompletionActual
Sep 14, 2026
Last update
Sep 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07479641
Responsible party
Sponsor
First posted
Mar 18, 2026
Start date
Apr 14, 2026
Primary completion
Sep 14, 2026
Completion
Sep 14, 2026
Last update
Sep 21, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion